Better molecules by design

Our innovative pipeline focuses on the development of a diverse array of next-generation therapies predicated on our 40 years of R&D work.

Each of these therapeutic modalities has shown incredible potential, with unique advantages in terms of treatment scenarios, bringing forth new options for powerful drugs that have previously been limited by toxicity concerns.

Product Candidates Therapeutic Index Research Development Pre-Clinical
  IM35-3 Immuno Oncology
  Adenosine Receptors A1|A2|A2a|A3
  IN21-3 Inflammation
  Multiple Targets
  CA 85-3 Cancer
  Multiple Targets
  DE 12-3 Depression
  Vasopressin & Serotonin Receptors
  CH 31-3 Chronic Pain
  Purinergic Receptor P2Y 1-6
  AN 4-3 Antipsychotics
  Dopamine D1 Receptor
  ANT 4 -2 Anticonvulsants
  Galanin Receptor 3
  ME 7-3 Metastasis
  AL 2-2 Allergy
  Uracil Nucleotide/ Cysteinyl Leukotriene Receptor
  DI 16-2 Diabetic
  Muscarinic Acetylcholine Receptor M1-5